Naltrexone in vivo protects μ receptors from inactivation by β-funaltrexamine, but not κ receptors from inactivation by nor-binaltorphimine

[1]  J. Woods,et al.  Clocinnamox: a novel, systemically-active, irreversible opioid antagonist. , 1992, The Journal of pharmacology and experimental therapeutics.

[2]  Declan Jones,et al.  Long term κ-opioid receptor blockade following nor-binaltorphimine , 1992 .

[3]  H. Yamamura,et al.  Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. , 1992, The Journal of pharmacology and experimental therapeutics.

[4]  T. Yaksh,et al.  Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists. , 1991, The Journal of pharmacology and experimental therapeutics.

[5]  C. Paronis,et al.  Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine. , 1990, The Journal of pharmacology and experimental therapeutics.

[6]  M. Millan.  Kappa-opioid receptor-mediated antinociception in the rat. I. Comparative actions of mu- and kappa-opioids against noxious thermal, pressure and electrical stimuli. , 1989, The Journal of pharmacology and experimental therapeutics.

[7]  P. Sánchez-Blázquez,et al.  Evaluation of δ receptor mediation of supraspinal opioid analgesia by in vivo protection against the β-funaltrexamine antagonist effect , 1989 .

[8]  P. Portoghese,et al.  Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. , 1988, The Journal of pharmacology and experimental therapeutics.

[9]  P. J. Birch,et al.  Norbinaltorphimine: Antagonist profile at κ opioid receptors , 1987 .

[10]  A. Lipkowski,et al.  Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. , 1987, Life sciences.

[11]  L. Liu-Chen,et al.  Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes. , 1986, The Journal of pharmacology and experimental therapeutics.

[12]  A. McKnight,et al.  Pre‐incubation of guinea‐pig myenteric plexus with β‐funaltrexamine: discrepancy between binding assays and bioassays , 1985, British journal of pharmacology.

[13]  D. L. Larson,et al.  Opioid receptor binding characteristics of the non-equilibrium μ antagonist, β-funaltrexamine (β-FNA)☆ , 1985 .

[14]  A. Goldstein,et al.  Site-directed alkylation of multiple opioid receptors. I. Binding selectivity. , 1984, Molecular pharmacology.

[15]  P. Portoghese,et al.  Pharmacological characterization in vivo of the novel opiate, beta-funaltrexamine. , 1982, The Journal of pharmacology and experimental therapeutics.